ACT-AD is a coalition of committed national organizations seeking to accelerate the development of potential cures and treatments to slow, halt or reverse the progression of Alzheimer’s disease through research.

Find Out More

This is where you can find out the latest in news from the coalition. To join ACT-AD, click here.

Find Out More
  • Activities

    August 30, 2013 ACT-AD Chairman Daniel Perry urges House and Senate Budget Committee leaders to take action on bi-partisan legislation to exempt FDA user fees from sequestration. The letters convey the importance of the user fee programs in funding timely and predictable drug, device, and biologic review activities and also describes how the FDA has been trying to maintain their direct review activities and pursue many of the exciting new initiatives included in the most recent authorizations of the prescription drug and medical device user fee programs, without collecting the full fees planned for this year. (More Info)

  • Take Action

    Today Alzheimer's disease, or AD, is a fatal diagnosis with death preceded by a slow, painful decline and loss of quality of life. The ACT-AD Coalition believes we have the ability to vastly improve the outlook for people with AD and thier caregivers in the next decade and we are committed to working with a diverse group of stakeholders to Accelerate a Cure and Treatments for Alzheimer's Disease. (More Info)

  • Latest News

    June 13, 2013 – –As potential AD drugs continue to post disappointing Phase 2/3 results, many in the field are considering upping the artillery by testing experimental drugs in combination. (More Info)